SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 163 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.68 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $1,735,563 | +119.1% | 68,195 | +106.8% | 0.65% | +162.8% |
Q3 2022 | $792,000 | -47.3% | 32,969 | -57.8% | 0.25% | -41.3% |
Q2 2022 | $1,504,000 | +83.2% | 78,182 | +65.5% | 0.42% | -27.2% |
Q1 2022 | $821,000 | -58.8% | 47,253 | -48.0% | 0.58% | +57.5% |
Q4 2021 | $1,991,000 | +12.8% | 90,934 | -1.6% | 0.37% | -22.7% |
Q3 2021 | $1,765,000 | +736.5% | 92,385 | +874.7% | 0.48% | +550.7% |
Q4 2020 | $211,000 | – | 9,478 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |